

Devyser wins tender for thalassemia in Italy

Devyser was awarded a tender for its NGS product Devyser Thalassemia, which is used for screening and confirmation of thalassemia, a hereditary blood disorder. The tender with Istituto Giannina Gaslini in Genova is valid for a period of 24 months. The indicative order value of the tender is estimated to be approximately 3.5 million SEK.

"The tender strengthens our already strong position in the Italian market, and I am very proud of the entire team who made this happen," says CEO Fredrik Alpsten. "This tender is another confirmation of the competitiveness and high quality of Devyser Thalassemia."

Thalassemia is a hereditary blood disorder associated with mild to severe anemia, bone problems, and slow growth in children. An estimated 5.2 percent of people carry a thalassemia-causing genetic mutation. Devyser Thalassemia, an end-to-end solution for screening and confirmation of thalassemia, gives users a comprehensive genetic profile for thalassemia gene clusters with a fast turnaround time and minimal hands-on time. The NGS workflow is suitable for any lab, whether running advanced genetic testing or large-scale mutation screening.

For more information, please contact:

Fredrik Alpsten, CEO

E-mail: fredrik.alpsten@devyser.com

Telephone: +46 70 667 31 06

Theis Kipling, CCO

E-mail: theis.kipling@devyser.com

Telephone: +46 73 598 07 76



PRESS RELEASE
27 May 2024 08:00:00 CEST

About Devyser

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit www.devyser.com.